Davis T, et al. Application of a validated prognostic plasma protein biomarker test for renal decline in type 2 diabetes to type 1 diabetes: the Fremantle Diabetes Study Phase II. Journal of Clinical Diabetes and Endocrinology, 2024.
PromarkerD Demonstrates Benefit of Early Treatment with SGLT2-inhibitors
Peters KE, et al. Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores. Journal of Clinical Medicine, 2023.
PromarkerD Predicts Late-Stage Renal Issues
Peters KE, et al. PromarkerD Predicts Late-Stage Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS). Poster presented at the American Diabetes Association’s 82nd Scientific Sessions, 2022.
Payer Budget Impact Study
Burchenal W, et al. Determination of Payer Budget Impact from Using an Innovative In Vitro Diagnostic in the Management of Diabetic Kidney Disease. Poster presented at Virtual ISPOR, 2021.
Economic Health Benefit Study
Burchenal W, et al. Demonstrating the Economic Health Benefit of using the PromarkerD In Vitro Diagnostic Test in the Prediction of Diabetic Kidney Disease. Poster presented at the American Diabetes Association’s 81st Scientific Sessions, 2021.
Drug Treatment Study
Peters KE, et al. Canagliflozin attenuates PromarkerD diabetic kidney disease risk prediction scores. Poster presented at the Australasian Diabetes Congress, 2021.
Clinical Utility Study
Fusfeld L, et al. Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis. PLOS ONE, 2021.
PromarkerD vs Standard of Care
Peters KE, et al. A Comparison of PromarkerD to Standard of Care Tests for Predicting Renal Decline in Type 2 Diabetes. Poster presented at ASN Kidney Week, 2021.
Global Multi-Centre Prognostic Validation Study
Peters KE, et al. PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS) J Clin Med. 2020.
Multi-Site Assay Validation Study
Bringans SD, et al. A robust multiplex immunoaffinity mass spectrometry assay (PromarkerD) for clinical prediction of diabetic kidney disease. Clin Proteomics. 2020.
Cross-Platform Assay Validation Study
Bringans SD, et al. The New and the Old Platform Cross-Validation of Immunoaffinity Mass Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease. Proteomes. 2020
Cross-Over Validation Study
Bringans SD, et al. PromarkerD as an immunoaffinity mass spectrometry assay for diabetic kidney disease. Poster presented at the 18th Human Proteome Organization World Congress. 2019
Cross-Platform Validation Study
Peters KE, et al. PromarkerD: A Novel Test for Predicting Rapid Decline in Renal Function in Type 2 Diabetes. Poster presented at the 18th Human Proteome Organization World Congress. 2019.
Biomarker Clinical Utility
Davis TME, et al. Apoptosis inhibitor of macrophage and diabetic kidney disease. Cell Mol Immunol. 2019.
Prognostic Validation Study
Peters KE, et al. Validation of a protein biomarker test for predicting renal decline in type 2 diabetes: The Fremantle Diabetes Study Phase II. J Diab Comp. 2019.
Diagnostic Study
Bringans SD, et al. Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease. EuPA Open Proteomics. 2017.
Prognostic Development Study
Peters KE, et al. Identification of Novel Circulating Biomarkers Predicting Rapid Decline in Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study Phase II. Diabetes Care. 2017.
DKD assessment using biomarkers
US Patent – Methods of Assessing Diabetic Nephropathy Using CD5 Antigen-Like
AB SCIEX Technote
Protein Biomarker Research Pipeline for Developing Protein Biomarkers for Diabetic Kidney Disease.
.png)
.png)